PacBio Files 8-K/A Amendment on Exit Costs

TL;DR

PacBio amended its 8-K filing regarding exit/disposal costs from April 16, 2024.

AI Summary

Pacific Biosciences of California, Inc. filed an amendment (8-K/A) on August 7, 2024, to its report originally filed on April 16, 2024. This amendment pertains to costs associated with exit or disposal activities, with the earliest event reported on April 16, 2024.

Why It Matters

This filing provides updated information regarding costs associated with the company's exit or disposal activities, which could impact its financial reporting and future operational plans.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report and concerns routine disclosure of exit or disposal costs, not a new material event.

Key Numbers

• 001-34899 — SEC File Number (Registrant's SEC file number)
• 16-1590339 — IRS Number (Registrant's IRS Employer Identification No.)

Key Players & Entities

• Pacific Biosciences of California, Inc. (company) — Registrant
• 0001299130-24-000165 (filing_id) — Accession Number
• April 16, 2024 (date) — Date of earliest event reported
• August 7, 2024 (date) — Filing Date of Amendment

FAQ

From the Filing

0001299130-24-000165.txt : 20240807 0001299130-24-000165.hdr.sgml : 20240807 20240807160935 ACCESSION NUMBER: 0001299130-24-000165 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240416 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 241183731 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K/A 1 pacb-20240416.htm 8-K/A pacb-20240416 0001299130 true Costs Associated with Exit or Disposal Activities 0001299130 2024-04-16 2024-04-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 16, 2024 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 2.05.    COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES. On April 16, 2024 Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”) filed a Current Report on Form 8-K regarding a plan to reduce its annualized run-rate operating expenses to better align its organizational structure and resources with its strategic initiatives (the “Expense Reduction Plan”). At that time the Company was unable to make a determination of the estimated amount or range of amounts to be incurred in connection with the Expense Reduction Plan. At this time, the Company expe